期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

索拉非尼研究进展 被引量：3

Recent progress of sorafenib
下载PDF
导出
摘要 索拉非尼(sorafenib)是一种口服的多激酶抑制剂,可以抑制肿瘤细胞增殖和血管增生,对肾癌和肝细胞癌均有效,对非小细胞肺癌、恶性黑色素瘤、甲状腺癌、乳腺癌、前列腺癌等的临床试验均在进行中。本文就索拉非尼的药代动力学、临床试验研究现状进行综述。 Sorafenib is an oral, mult-kinase inhibitor which inhibits tumor proliferation and angiogenesis. Clinical trials had revealed that sorafenib was effective in treatment of renal cell carcinoma, hepatocellular carcinoma. Effects of sorafenib on NSCLC, melanoma, thyroid carcinoma, breast carcinoma and prostate carcinoma were under investigation. The pharmacokinetics and clinical research of sorafenib were reviewed.
作者 刘健颖 唐伟方 陆涛
机构地区 中国药科大学有机化学教研室
出处 《海峡药学》 2010年第4期9-11,共3页 Strait Pharmaceutical Journal
关键词 索拉非尼 肿瘤细胞增殖 非小细胞肺癌 恶性黑色素瘤 临床试验 药代动力学 血管增生 肝细胞癌 Sorafenib Clinical study Neoplasm
分类号 R969.4 [医药卫生—药理学] R979.1 [医药卫生—药品]
  • 相关文献

参考文献22

  • 1Chang YS,Adnane J,Trail PA,et al Sorafenib(BAY43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hy-poxia in RCC xenograftmodels[J].Cancer Chemother Pharmacol.2007,59(5):561-574.
  • 2郭玉峰.索拉非尼的最近研究概况[J].中国医疗前沿,2009,4(5):30-31. 被引量：5
  • 3Escudier B,Eisen T,Stadler WM,et al.Sorafenib in advanced clear-cell renal-cell carcinoma[J].N Engl J Med,2007,356(2):125-134.
  • 4Amato RJ,Harris P,Dalton M,et al.A phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer(MRCC)[J].J Clin Oncol,2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition).Vol 25,No 18S(June 20 Supplement),2007,5026.
  • 5Llovet JM,Ricci S,Mazzaferro V,et al.Sorafenib in advanced hepato-cellular carcinoma[J].N Engl J Med,2008.359(4):378-390.
  • 6Axel Hauschild,Sanjiv S.A.,Uwe Trefzer,et al.Results of a Phase Ⅲ,Randomized,Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage Ⅲ or Stage Ⅳ Melanoma[J],J Clin Oncol,2009.27(17):2823-2830.
  • 7David F.M.Jeffrey A.S.,et al Double-Blind Randomized Phase Ⅱ Study of the Combination of Sorafenib and Dacarbazine in Patients With Advanced Melanoma:A Report From the 11715 Study Group[J].J Clin Oncol,2008,26(13):2178-2185.
  • 8Ravi K.A.,Lynn M.S.,et al Phase Ⅱ Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases[J].Clin Cancer Res,2009,15(24):7711-7718.
  • 9George R.B.Ulrich G.,et al Phase Ⅱ,Multicenter,Uncontrolled Trial of Single-Agent Sorafenib in Patients With Relapsed or Refractory Advanced Non-Small-Cell Lung Cancer[J].J Clin Oncol,2009,27 (26):4274-4280.
  • 10Adjei A.A.,Molina J.R.,et al.Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer[J].Clin Cancer Res.2007,13(9):2684-2691.

二级参考文献31

  • 1寿建忠,马建辉,孙燕.索拉非尼治疗实体瘤的基础实验和临床试验研究现状[J].癌症进展,2007,5(3):286-289. 被引量：4
  • 2丁丽,程刚.多靶点抗肿瘤新药索拉非尼的药理作用及临床研究进展[J].药物不良反应杂志,2007,9(3):153-157. 被引量：12
  • 3Escudier B,Szczylik C,Eisen T,et al. Randomized phase Ⅲ trial of the Raf kinase and VEGFR inhibitor sorafenib ( BAY 43-9006 ) in patient with advanced renal cell carcinoma [ J ]. J Clin Oncol, 2005,23 (Suppl) : a4510.
  • 4Wilhelm S M,Carter C,Tang L,et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis[ J]. Cancer Res,2004,64(19) :7099 - 109.
  • 5Strumberg D, Clark J W, Schwartz B, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib : a review of four phase I trial in patients with advanced refractory solid tumors[J]. Oncologist,2007,12 (4) :426 - 37.
  • 6Richly H,Henning B F,Strumberg D,et al. Results of a Phase 1 trial of sorafenib ( BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors [ J ]. Ann Oncol, 2006,17 (5) :866 -73.
  • 7Strumberg D, Richly H, Hilger R A, et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY43-9006 in patients with advanced refractory solid tumors [ J ]. J Clin Oncol, 2005,23 (5) :965 -72.
  • 8Moore M,Hirte H W,Siu L,et al. Phase I study to determine the safety and pharma-cokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006 ,administered for 28 days on/7 days off in patients with advanced, refractory solid tumors [J]. Ann Oncol, 2005,16(10) : 1688 -94.
  • 9Ratain M J, Eisen T, Stadler W M, et al. Phase lI placebo-controlled randomized discontinuatoin trial of Sorafenib in patients with advanced renal cell carcinoma[J]. J Clin Oncol,2006,24(16) :2505 -12.
  • 10Escudier B,Eisen T,Bukowski R M,et al. Sorafenib in advanced clear-cell carcinoma[J]. N Engl J Med,2007 ,356( 2 ) :125 -34.

共引文献39

同被引文献29

  • 1刘亚方,李小刚,李洪玉,李金岭,姜申德.索拉非尼的合成研究[J].精细化工中间体,2012,42(5):36-39. 被引量：6
  • 2Kim AR, Balls FM, Widemann BC. Sor- afenib and sunitinib. Oncologist, 2009, 14:800-805.
  • 3Huether A,Hopfner M,Baradari V,et al. Sor- afenib alone or as combination therapy for growth control of cholangiocarcinoma. Bio- chem Pharmaco! ,2007,73 : 1308-1317.
  • 4Blechacz BRA, Smoot RL, Bronk SF, et al. Sorafenib inhibits signal transducer and activator of transcription - 3 signaling in cholangi cells by activating the phosphatase shatterproof 2. Hepatology 2009,50 : 1861-1870.
  • 5Bengala C, Bertolini F, Malavasi N, et al. Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. Br J Cancer, 2009,102 : 68 -72.
  • 6EI-Khoueiry AB, Rankin CJ, Ben-Josef E, et al. SWOG 0514 : a phase II study of sor- afenib in patients with unresectable or me- tastatic gallbladder carcinoma and cholan- giocarcinoma. Invest New Drugs, 2011, 30 : 1646-1651.
  • 7Rosato RR, Almenara JA, Coe S, et al. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res, 2007, 67 : 9490-9500.
  • 8隋忠国,薛宏伟,荆凡波,冷萍.索拉非尼联合卡培他滨治疗肝细胞癌患者的临床研究[J].中国药房,2008,19(11):848-849. 被引量：20
  • 9赵海涛,李宁,桑新亭,毛一雷.肝癌靶向治疗的研究进展[J].癌症进展,2008,6(3):293-298. 被引量：8
  • 10邹声泉.胆管癌分子生物学特性研究进展[J].中华实验外科杂志,2009,26(12):1585-1587. 被引量：4

引证文献3

二级引证文献6

海峡药学
2010年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部